SunBio PEGylation technology and PEG products have played a crucial role in many successfully
marketed biosimilar, biopharmaceutical and medical devices products worldwide.
The healthcare products under development at SunBio are listed in the table.
Category | Product/Candidate | Status | Launch |
---|---|---|---|
Biosimilar | PEG-filgrastim Biosimilar | Marketed | 2018 EU 2018 Canada 2008 India |
PEG-EPO Biosimilar | Preclinical | 2023 (forecast) | |
Medical Device | Xerostomia Treatment (MucoPEG) |
2018 FDA filing planned | 2019 (forecast) |
Viscosupplement for Arthritic Knee (SynoGEL) |
2021 FDA filing planned | 2022 (forecast) | |
Biopharmaceutical | Brain Stroke Treatment (SB1) | Preclinical | 2025 (forecast) |
Diabetic Retinopathy Treatment (SB2) | Preclinical | 2025 (forecast) | |
Anemia Treatment (SB7) | Preclinical | 2028 (forecast) | |
PEG Product | PEG Derivatives Manufacture and Sales | Marketed | Worldwide |